AI Article Synopsis
- This review focuses on the current state of kidney tumor ablation for patients with severe kidney impairment, specifically those with stage 4 or 5 chronic kidney disease (CKD).
- Recent studies show that 2.0%-10% of ablation patients have advanced CKD, with local tumor control rates ranging from 88%-100%, but the impact of ablation on kidney function remains uncertain.
- Although complete tumor removal and maintenance of kidney function are key treatment goals achievable through ablation, the option of active surveillance may also be recommended due to the limited treatment choices available for these patients.
Article Abstract
Purpose Of Review: To review the current status of kidney tumor ablation in patients with substantial kidney impairment.
Recent Findings: Few reports of kidney tumor ablation in such patients have recently been published. The reported prevalence of patients with stage 4 or 5 chronic kidney disease (CKD) among patients undergoing ablation is 2.0%-10%. In patients with stage 4 or 5 CKD, local tumor control rates were 88%-100%. The effect of ablation on CKD stage is unclear, and the observed deteriorations in kidney function are consistent with both the effect of cryoablation and the natural course of advanced CKD. According to guidelines, active surveillance may be selected. The goals of treatment are complete tumor removal and maintenance of kidney function, both of which can be met by ablation. Given the limited treatment options, ablation may play a pivotal role in the management of patients with advanced CKD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11912-024-01533-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!